An innovative lifestyle intervention called Super Rehab, which has been trialled at the Royal United Hospitals Bath NHS ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

IB-T101 demonstrated superior preclinical efficacy in an aggressive renal cell tumor model, significantly outperforming ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

Results from the Phase II pivotal incontinence trial saw 42% of patients being declared completely dry, and 82% seeing a ...

THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...